TGFB1 and atherosclerosis: As TGF-β is a key driver of EndMT, there is work showing that limiting endothelial responses to TGF-β (i.e., by endothelial-specific Tgfbr1/2 knock out in mouse models of atherosclerosis) limits EndMT, decreases inflammation and plaque progression, and even facilitates plaque regression (65).